The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
Subscribe To Our Newsletter & Stay Updated
